

Adolescent COVID-19 Vaccination

The Pfizer-BioNTech COVID-19 vaccine is now authorized and recommended for the prevention of COVID-19 disease in persons 12 years of age and older. On May 12, 2021, the Centers for Disease Control and Prevention (CDC) [announced](#) expanded use of the Pfizer-BioNTech COVID-19 vaccine to adolescents ages 12–15 years old. The official CDC recommendation follows the Food and Drug Administration’s (FDA) decision to [authorize](#) emergency use of the Pfizer-BioNTech vaccine in this population on May 10, 2021.

Quick Links

- CDC’s [Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit](#)
- CDC’s [COVID-19 Vaccines for Children and Teens](#)
- CDC’s [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States—Vaccination of Children and Adolescents](#)
- FDA’s Pfizer-BioNTech COVID-19 Vaccine [EUA Fact Sheet for Healthcare Providers](#) and for [Recipients and Caregivers](#)

What is the Pfizer-BioNTech COVID-19 vaccine dosing regimen for adolescents ages 12-15 years old?

The dosing regimen for this population is the same as adults. Adolescents aged 12-15 years old should receive 2 doses (0.3mL each) 21 days apart.

Who is authorized to order and administer the Pfizer-BioNTech COVID-19 vaccine at the pharmacy?

The U.S. Department of Health and Human Services (HHS) expanded COVID-19 vaccination authority under the [Public Readiness and Emergency Preparedness \(PREP\) Act](#) for pharmacists, pharmacy technicians, student pharmacists and interns, and retired or inactive pharmacists and interns nationwide during the public health emergency. Each of these pharmacy team members may administer the COVID-19 vaccines to persons 3 years of age and older, as recommended. **Pharmacists can order the Pfizer-BioNTech vaccine for eligible persons ages 12 and up. No prescription is required.** For more information, refer to “Authority to Immunize During COVID-19” in APhA’s Know the Facts [practice resource library](#).

What evidence is available to support the safety and efficacy of the Pfizer-BioNTech COVID-19 vaccine in adolescents?

CDC [reports](#) that a study of 2,200 participants ages 12-15 years old found that the Pfizer-BioNTech COVID-19 vaccine was 100% effective in preventing COVID-19. No safety concerns were identified.



Adolescent COVID-19 Vaccination (continued)

Should other vaccines be co-administered with the Pfizer-BioNTech COVID-19 vaccine?

All authorized COVID-19 vaccines, including the Pfizer-BioNTech COVID-19 vaccine, **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days.

It is unknown whether the reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to co-administer other vaccine(s) with COVID-19 vaccines, providers should consider:

- Whether the patient is behind or at risk of becoming behind on recommended vaccines
- The patient risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and
- The reactogenicity profile(s) of the vaccines.

What steps should vaccine providers take when administering multiple vaccines during a single visit?

If multiple vaccines will be administered during a single visit, administer each injection at a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection.

[Best practices](#) for multiple injections include:

- Separate injection sites by one inch or more, if possible.
- Administer the COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (e.g., tetanus-toxoid-containing and adjuvanted vaccines) in different limbs, if possible.

How should adolescents be monitored after vaccination?

The [post-observation time](#) and process is the same for adolescents as it is for adults. Individuals with no history of allergic reaction should be monitored for 15 minutes. Adolescents with a history of allergic reaction should be monitored for 30 minutes.

Adolescents may be at increased risk of experiencing a syncopal (fainting) episode after receiving any immunization, including COVID-19. Providers should pay particular attention to potential syncope reactions in this age group.

What should adolescents and their caregivers expect after vaccination?

Post-vaccination symptoms are common, such as a sore arm, redness at the injection site, fever, fatigue, headache, and chills. For all currently authorized COVID-19 vaccines, antipyretic or analgesic medications (e.g., acetaminophen, non-steroidal anti-inflammatory drugs) can be taken for the treatment of post-vaccination local or systemic symptoms, if medically appropriate. However, routine prophylactic administration of these medications for the purpose of preventing post-vaccination symptoms is not currently recommended.

Adolescent COVID-19 Vaccination (continued)

What steps should caregivers take to monitor for safety related to COVID-19 vaccination?

[V-safe](#) has been updated to allow parental input and management. Parents or guardians can register their adolescent children in v-safe and complete the health surveys on their behalf. CDC's v-safe call center follows up on reports to v-safe that include possible medically significant health events to collect additional information for completion of a VAERS report.

What steps should vaccination providers take to monitor for safety related to COVID-19 vaccination?

Vaccination providers are required to report vaccination administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after administration of COVID-19 vaccine under an emergency use authorization (EUA).

Adverse events that occur after receipt of any COVID-19 vaccine should be reported to the [Vaccine Adverse Events Reporting System \(VAERS\)](#). Information on how to submit a report to VAERS is available at their website or 1-800-822-7967.

What additional requirements should pharmacies be prepared to meet?

If the patient is 18 years of age or younger, the vaccination provider must inform the patient and the adult caregiver accompanying the patient of the importance of a well-child visit with a pediatrician or other licensed primary care provider and refer patients as appropriate. The following materials were designed by APhA and others to help pharmacy teams meet this requirement:

- [Well-Child Visit Brochure](#)
- [Template Referral Form Well-Child Visit](#)
- [Well-Child Checkup Letter](#)

Disclaimer: The information in this document is provided only for general informational purposes and does not constitute business or legal advice. Information related to the COVID-19 pandemic is changing rapidly and continuously. The material and information contained in this publication is believed to be current as of the date included on this document. The American Pharmacists Association assumes no responsibility for the accuracy, timeliness, errors, or omission contained herein. Links to any sources do not constitute any endorsement of, validity, or warranty of the information contained on any site. The user of these materials should not under any circumstances solely rely on, or act based on this publication. Pharmacy professionals retain the responsibility for using their own professional judgment and practicing in accordance with all rules, regulations, and laws governing the pharmacy practice within their jurisdiction.